← Leaderboards
Rosalyn D Blumenthal
Ctr For Molecular Medicine/Immunology
$4,498,008
Attributed
$4,498,008
Total exposure
10
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding mix
By agency
NIH$4,498,008 · 10
By mechanism
R01$3,128,553 · 2
P01$779,800 · 5
R21$577,500 · 2
P41$12,155 · 1
Top collaborators
No co-investigators on record.
Most similar at Ctr For Molecular Medicine/Immunology
Same institution · by research overlap
- Robert M Sharkey$7,941,617
- David M Goldenberg$649,937
- David V Gold$4,477,124
- M Jules Mattes$1,208,134
- Rhona N Stein$2,287,648
Others in their field
Top investigators on “Athymic Mouse”
- Thomas F Deuel · Beth Israel Deaconess Medical Center$7,283,721
- Ralph Weissleder · Massachusetts General Hospital$5,688,124
- Donald P McDonnell · Duke University$5,386,390
- Oliver W. Press · Fred Hutchinson Cancer Research Center$5,178,285
- Channing J Der · University Of North Carolina Chapel Hill$4,926,790
- Murray Korc · University Of California Irvine$4,764,672
Research focus
Athymic MouseCombination Cancer TherapyNeoplasm /Cancer ChemotherapyDoxorubicinBreast NeoplasmsPaclitaxelNonhuman Therapy EvaluationPolymerase Chain ReactionTopotecanApoptosisGene ExpressionOvary NeoplasmsCarboplatinDrug ResistanceTechnology /Technique DevelopmentImmunomagnetic SeparationHuman SubjectNeoplasm /Cancer RadioimmunotherapyDisease /Disorder ModelCell LineNeoplasm /Cancer Radiation TherapyClinical ResearchNeoplasm /Cancer ImmunotherapyTransfection
Grant awards (13)
Animal Studies$195,052
P01 · FY2008 · CA · contact PI
PRE-CLINICAL COMBINATION CHEMO- AND RADIOANTIBODY THERAP$977,147
R01 · FY2004 · CA
PRE-CLINICAL COMBINATION CHEMO- AND RADIOANTIBODY THERAP$922,425
R01 · FY2003 · CA
Chronobiological Principles to Maximize Efficacy of Alt*$292,500
R21 · FY2003 · CA
PRE-CLINICAL COMBINATION CHEMO/RADIOANTIBODY THERAPY$948,718
R01 · FY2002 · CA
PRE TARGETED THERAPY USING THE NOVEL TACHYKININ (NK) REC$142,500
R21 · FY2001 · CA
FACTORS IN COMBINED RADIOIMMUNOTHERAPY AND CHEMOTHERAPY IN CANCER MANAGEMENT$292,374
P01 · FY2000 · CA
CORE--ANIMAL LABORATORY$292,374
P01 · FY2000 · CA
RADIOIMMUNOTHERAPY AND TUMOR VASCULAR PHYSIOLOGY$280,263
R01 · FY2000 · CA
PRE TARGETED THERAPY USING THE NOVEL TACHYKININ (NK) REC$142,500
R21 · FY2000 · CA
EFFECT OF TARGETED LOW DOSE RADIATION TREATMENT ON TUMOR OXYGENATION$12,155
P41 · FY2000 · RR
CORE--ANIMAL EXPERIMENTATION$0
P01 · FY2000 · CA
RATIONAL DESIGN OF CHEMO AND RADIOANTIBODY THERAPY$0
P01 · FY2000 · CA